MedTrace Logo

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

NCT06318871 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-05-11

No results posted yet for this study

Summary

The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma.

Names of the study therapies involved in this study are/is:

* CIML NK cell therapy (a NK cell therapy)
* IL-2 (a type of cytokine)

Conditions

Interventions

BIOLOGICAL

Cytokine Induced Memory-like Natural Killer (CIML NK) Cells

Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.

DRUG

Interleukin-2 (IL-2)

Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity

Sponsors & Collaborators

Principal Investigators

  • Wenxin Xu, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-28
Primary Completion
2027-02-28
Completion
2031-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06318871 on ClinicalTrials.gov